X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Rabian BV
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Partnership February 28, 2024
Details:
The collaboration aims to support Dyadic's in microbial platforms for flexible-scale protein bioproduction and the IIBR’s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Israel Institute for Biological Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 21, 2024
Details:
The collaboration aims to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform, targeting infectious and other diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 06, 2024
Details:
DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor-binding domain (RBD) recombinant protein booster vaccine candidate, highly expressed in Dyadic's proprietary C1-cell protein production platform for the prevention of COVID-19.
Lead Product(s): DYAI-100
Therapeutic Area: Infections and Infectious Diseases Product Name: DYAI-100
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
The collaboration aims to use Dyadic’s proprietary C1 protein production platform for rapid production of prophylactic vaccines for influenza A and other infectious diseases.
Lead Product(s): Prophylactic Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: Vaccine and Immunotherapy Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 05, 2023
Details:
DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor binding domain recombinant protein booster vaccine candidate, highly expressed in dyadic's proprietary C1-cell protein production platform for the prevention of covid-19.
Lead Product(s): DYAI-100
Therapeutic Area: Infections and Infectious Diseases Product Name: DYAI-100
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
The Patent will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company's C1 protein production platform.
Lead Product(s): Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
The agreement aims to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries using Dyadic's C1-cell protein expression platform.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: Rubic One Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 12, 2023
Details:
DYAI-100, also known as C1-SARS-CoV-2 RBD vaccine, is a novel receptor binding domain recombinant protein booster vaccine candidate, highly expressed in Dyadic's proprietary C1-cell protein production platform for the prevention of COVID-19.
Lead Product(s): DYAI-100
Therapeutic Area: Infections and Infectious Diseases Product Name: DYAI-100
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine, produced using the C1 platform, administered as a booster vaccine at two single dose levels in healthy volunteers.
Lead Product(s): DYAI-100
Therapeutic Area: Infections and Infectious Diseases Product Name: DYAI-100
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
